Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathological complete response with neoadjuvant pembrolizumab and chemotherapy in non-metastatic triple-negative inflammatory breast cancer.

ESMO open·2026
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Light Long-Lived Particles in pp Collisions at sqrt[s]=13  TeV Using Displaced Vertices in the ATLAS Inner Detector.

Physical review letters·2024
Same author

Search for the Exclusive W Boson Hadronic Decays W^{±}→π^{±}γ, W^{±}→K^{±}γ and W^{±}→ρ^{±}γ with the ATLAS Detector.

Physical review letters·2024
Same author

Determination of the Relative Sign of the Higgs Boson Couplings to W and Z Bosons Using WH Production via Vector-Boson Fusion with the ATLAS Detector.

Physical review letters·2024

Related Experiment Video

Updated: Mar 27, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K

Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.

K Raghav1, J T French2, N T Ueno3,4

  • 1Department of Gastrointestinal Medical Oncology, Divison of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

Plos One
|January 12, 2016
PubMed
Summary
This summary is machine-generated.

Histologic subtypes in inflammatory breast cancer (IBC) were analyzed. Lobular histology, found in 4.5% of IBC cases, did not significantly impact patient survival outcomes.

More Related Videos

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.4K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 27, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K
High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts
06:06

High-Throughput Dissociation and Orthotopic Implantation of Breast Cancer Patient-Derived Xenografts

Published on: December 20, 2024

1.4K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Oncology
  • Pathology
  • Cancer Research

Background:

  • Histologic subtypes are well-recognized in breast cancer but not previously described in inflammatory breast cancer (IBC).
  • Understanding these subtypes is crucial for accurate diagnosis and treatment of IBC.

Purpose of the Study:

  • To describe the lobular subtype in inflammatory breast cancer (IBC).
  • To assess the impact of different histologic subtypes on patient outcomes in IBC.

Main Methods:

  • Retrospective analysis of 659 IBC patients (1984-2009).
  • Comparison of Invasive Lobular Carcinoma (ILC), Mixed Invasive Ductal and Lobular Carcinoma (MIC), and Invasive Ductal Carcinoma (IDC) patient characteristics and survival.
  • Statistical analysis using chi-square, Kaplan-Meier, and Cox proportional hazards models.

Main Results:

  • Invasive lobular histology was identified in 4.5% of IBC cases.
  • Grade 3 tumors were more frequent in ductal histology (78%) compared to lobular (60%) or mixed (61%).
  • No significant difference in 3-year overall survival rates was observed among lobular, mixed, and ductal IBC groups (68%, 64%, 62% respectively).
  • Histology did not significantly affect survival outcomes after adjustment for other factors.

Conclusions:

  • Lobular histology is present in a small subset of IBC patients.
  • Unlike non-inflammatory breast cancer, histologic subtype does not appear to significantly influence survival in IBC.
  • This suggests a distinct biological behavior of the IBC phenotype compared to non-inflammatory breast cancer.